Overview
- Species: Other
- Keywords: HyStem®/hyaluronic acid
- Specific Attributes: sterile
Heprasil® Hyaluronan Acid
Cat.-Nr.: GS217-5EA
Description
Heprasil® is thiol-modified hyaluronic acid with thiol-modfied heparin and is a component of the HyStem® hydrogel kit. Hyaluronic acid is a major constituent of native extracellular matrix (ECM). Heparin is also present in the ECM as heparan sulfate. Most cells do not attach to Heprasil-only hydrogels. Heprasil must be used in conjunction with Gelin-S® or ECM proteins such as laminin, collagen, or fibronectin for most 3-D cell culture and tissue-engineering applications.
Gelation
Reconstituted Heprasil remains liquid at 15 to 37°C. Without a crosslinker, Heprasil will form a hydrogel via disulfide bond formation; however, the gelation time is over twenty-four hours. If Extralink® is used to crosslink the Heprasil, the gelation time is about twenty minutes with no low-temperature or low-pH steps. Diluting Heprasil with phosphate-buffered saline (PBS) or cell-culture medium can increase its gelation time.
SUPPLIER:
Advanced BioMatrix
STATUS:
In Stock
SIZE:
5 x 1 ml
Related Files
References
- References for HyStem®:
- Maloney, E. et al.Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput. Micromachines 11, 208 (2020).
- Gaetani, R., et al. (2015) Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction. Biomaterials 61: 339-348. PMID: 17335875.
- Prestwich, G.D., et al. (2007) 3-D culture in synthetic extracellular matrices: new tissue models for drug toxicology and cancer drug discovery. Adv Enzyme Regul 47: 196-207. PMID: 17335875.
- Shu, X.Z., et al. (2006) Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A 79: 901-912. PMID: 16941590.
- Shu, X.Z., et al. (2003) Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 24: 3825-3834. PMID: 12818555.
- Cai, et al. (2005) Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor.Biomaterials, 26, 6054-6067.
- B. Pike, et al. (2006) Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials, 27, 5242–5251.
- D. Prestwich, et al. (2007) 3-D Culture in Synthetic Extracellular Matrices: New Tissue Models for Drug Toxicology and Cancer Drug Discovery. invited, Adv. Enz. Res., in press (2007).
- Z. Shu, et al, (2006) Synthesis and Evaluation of Injectable, In Situ Crosslinkable Synthetic Extracellular Matrices (sECMs) for Tissue Engineering. J. Biomed Mater. Res. A, 79A(4), 901-912.
- Shu, X.Z., et al. (2004) In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25: 1339-1348. PMID: 14643608.
- Mehra, T.D., et al. (2006) Molecular stenting with a crosslinked hyaluronan derivative inhibits collagen gel contraction. J Invest Dermatol 126: 2202-2209. PMID: 16741511.
- Shu, X.Z., et al. (2004) Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Mater Res A 68: 365-375. PMID: 14704979.
- Ghosh, K., et al. (2007) Cell adaptation to a physiologically relevant ECM mimic with different viscoelastic properties. Biomaterials 28: 671-679. PMID: 17049594.
Glycosil® Hyaluronan Acid